替加环素与米诺环素治疗布鲁菌病的进展

布鲁菌病是由布鲁菌引起的人畜共患传染病,由带菌动物通过多种途径传染给易感人群。目前布鲁菌病治疗方案为多西环素、利福平、喹诺酮类、氨基糖苷类等抗菌药物组合的二联或者三联抗菌方案,但治疗无效率和疾病复发率仍较高。替加环素和米诺环素作为四环素类药物,经体外实验证明均可有效抑制布鲁菌,且50%最小抑菌浓度(50%minimal inhibitory concentration,MIC 50)和90%最小抑菌浓度(90%minimal inhibitory concentration,MIC 90)均较低。临床研究亦证实,包含替加环素和米诺环素的联合抗菌方案具有较低的治疗无效率和疾病复发率。因此,替加环素和米诺环素可作为治疗布鲁菌病的候选用药。本文就布鲁菌病传统治疗方案以及替加环素和米诺环素的抗菌效果进行综述。

Progress in the treatment of brucellosis

Brucellosis is a contagious disease caused by brucella. It is transmitted from carrier animals to susceptible people through multiple transmission methods. It is a common disease in clinical. The currently recommended anti-brucella regimens include double and triple antibacterial combination consisting of doxycycline, rifampicin, quinolone drugs and aminoglycosides and so on. But the failure rate and relapse rate are still high. Tigecycline and minocycline as tetracyclines can be selected as candidates. Brucella is sensitive to both drugs in vitro experiments. Fifty percent minimal inhibitory concentration (MIC50) and 90% minimum inhibitory concentration (MIC90) of the two drugs were low. Clinical studies have also confirmed that combined antibacterial regimens containing tigecycline and minocycline have lower failure rate and relapse rate. Therefore, tigecycline and minocycline can be candidates for the treatment of brucellosis.